Case 10-2011: Fever, confusion, and liver failure by Netea, M.G. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
correspondence
n engl j med 365;2 nejm.org july 14, 2011 185
also critical in the care of patients with respira-
tory disorders or unbalanced pH and that these 
disorders cannot be evaluated with the use of pulse 
oximetry. In particular, a normal pulse oximetry 
measurement does not exclude important abnor-
malities in the partial pressure of arterial carbon 
dioxide (PaCO2) or pH. Therefore, serious eleva-
tions in the PaCO2, which are indicative of venti-
latory dysfunction, can be present when the re-
sults of pulse oximetry are normal.2 Although 
noninvasive, transcutaneous CO2 monitoring can 
be used to complement pulse oximetry, current 
technologies still require further development and 
are not indicative of acid–base status.3 Thus, cli-
nicians need to be aware that levels of arterial and 
capillary blood gases remain a critical component 
of the evaluation of gas exchange.
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The Authors and a Colleague Reply: Avidan 
and Levin point out that the determination of he-
moglobin concentrations for pulse oximetry are 
approximations. In the formulas shown in the vid-
eo, we could have indicated that hemoglobin var-
iables are estimates of the underlying true concen-
trations by inserting a tilde or a caret above the 
abbreviation for hemoglobin (Ĥb), but we made 
the decision to use a simplified approach to clar-
ify the teaching point, as is done in many text-
books.
Even the reference measurement of SaO2 in ar-
terial blood performed by our institution’s blood 
gas laboratory involves the estimation of the rela-
tive concentrations of oxyhemoglobin and deoxy-
hemoglobin in an arterial blood sample with the 
use of infrared absorption co-oximetry. One can 
argue that all measurements are estimates and 
that the question of whether a particular monitor-
ing technique constitutes a measurement or an 
estimate becomes semantic.
Regarding the inability of pulse oximetry to 
detect hypercarbia and metabolic disturbances, 
Man and Marsden bring up important points. 
Pulse oximetry is an excellent oxygenation mon-
itor, but it does not alert the clinician to chang-
es in ventilation in a timely manner, particularly 
when supplemental oxygen is used. Anesthesi-
ologists are well aware of this limitation of pulse 
oximetry and recommend the use of capnogra-
phy to monitor ventilation during procedural se-
dation.
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Case 10-2011: Fever, Confusion, and Liver Failure
To the Editor: With regard to the Case Record 
of a 60-year-old woman with fever, confusion, 
and liver failure (March 31 issue)1: we are inter-
ested in Tierney’s thoughts on the possibility that 
the combined use of pegylated interferon and ri-
bavirin to treat the patient’s hepatitis C induced 
an autoimmune liver disease that contributed to 
her death.2,3 Her confusion and asterixis (sug-
gesting hepatic encephalopathy), the markedly 
elevated levels of transaminases and the associ-
ated positive test result for autoimmune markers, 
and the response to glucocorticoids lead us to sus-
pect a diagnosis of autoimmune liver disease. We 
are also curious as to whether the preexistence of 
cirrhosis affects the decision to include spleno-
megaly in the diagnostic criteria for hemophago-
cytic lymphohistiocytosis.
Christopher Kandel, M.D. 
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To the Editor: Tierney et al. present the case of 
a woman with hemophagocytic lymphohistio-
cytosis who is treated with immunosuppressive 
therapy. Unfortunately, after an initial improve-
ment, severe infectious complications developed 
that led to her death. Hemophagocytic syndrome is 
caused by the uncontrolled activation of macro-
phages and the release of proinflammatory cyto-
kines (a cytokine storm). However, this activation 
concerns the macrophage-derived proinflammatory 
cytokines of the interleukin-1 family (interleukin-
1α and 1β and interleukin-18), whereas levels of 
T-cell–derived cytokines, such as interferon-γ, are 
much less increased.1 Classic immunosuppressive 
agents indiscriminately inhibit all components of 
host defense, leading to severe complications, but 
a more refined strategy has been used successfully 
in the treatment of hemophagocytic syndrome. 
Inhibition of the effects of interleukin-1 by its 
receptor antagonist (interleukin-1Ra, or anakinra) 
dampens systemic inflammation while leaving 
untouched host defense mechanisms such as spe-
cific cellular immunity.2-4 Anakinra has also been 
used successfully and with few infectious com-
plications in the treatment of other autoinflam-
matory conditions related to hemophagocytic syn-
drome.5 Therefore, anakinra might be considered 
as an alternative therapy, with less severe com-
plications, in patients with hemophagocytic syn-
drome.
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To the Editor: The presentation of the second 
patient in this case, a young man with fatal he-
mophagocytic lymphohistiocytosis and active in-
fection with the Epstein–Barr virus, is reminis-
cent of X-linked lymphoproliferative disease, or 
Duncan’s syndrome (Online Mendelian Inheri-
tance in Man [OMIM] number, 308240), which 
is caused by mutations in SH2D1A,1 or of X-
linked familial hemophagocytic lymphohistiocy-
tosis (OMIM number, 300635), caused by BIRC4 
mutations.2,3 In the presence of SH2D1A mutations, 
serum amyloid P (SAP) component is truncated or 
absent, which disrupts its capacity to bind with 
the family of receptors known as SLAM (signal-
ing lymphocytic activation molecule), which in 
turn disrupts the related signal transduction path-
ways. The mechanism through which BIRC4 mu-
tations result in the disease phenotype remains 
unknown. Patients may be asymptomatic until the 
occurrence of a disease-initiating event, such as 
infection with Epstein–Barr virus. Patients harbor-
ing SH2D1A or BIRC4 mutations may present with 
hemophagocytic lymphohistiocytosis or dysgam-
maglobulinemia in association with the virus, but 
malignant lymphoma develops only in those with 
SH2D1A mutations.4 If this young man’s DNA is 
available, it should be tested for SH2D1A and BIRC4 
mutations (given informed consent from a mem-
ber of the immediate family).
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Eosinophil Granule Protein Localization in Eosinophilic 
Endomyocardial Disease
To the Editor: A 70-year-old man with chronic 
renal disease, splenomegaly, and eosinophilia pre-
sented with transient weakness in the left arm, 
visual disturbances, disequilibrium, and anomia. 
Magnetic resonance imaging of the brain showed 
findings consistent with numerous, small em-
bolic strokes. Four echocardiograms, including a 
transesophageal echocardiogram, did not reveal 
abnormalities. Therapeutic trials of glucocorti-
coids and imatinib were unsuccessful at reducing 
the numbers of peripheral-blood eosinophils. To 
investigate the possibility that the emboli were 
the sequelae of eosinophilic endomyocardial dis-
ease, the patient underwent a biopsy of his right 
ventricle and intraventricular septum. Staining of 
the myocardium with hematoxylin and eosin did 
not show clinically significant abnormalities. No-
tably, only rare eosinophils were detected in the 
interstitium (Fig. 1A and 1B). However, immuno-
histologic examination with fluorescein-conjugat-
ed antibodies to eosinophil granule major basic 
protein 1 (MBP1) revealed striking extracellular 
deposits of eosinophil granule MBP1 (Fig. 1C and 
1D). The eosinophil granule MBP1 was most prom-
inent at apparent luminal surfaces, especially over 
an area of endocardium that stained most in-
tensely. 
Eosinophilic endomyocardial disease is a com-
plication of the hypereosinophilic syndrome. 
A previous study showed eosinophil infiltration 
and deposition of toxic eosinophil granule proteins 
in damaged cardiac tissues.2 Eosinophil granule 
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The Discussants Reply: The suggestion from 
Kandel and Kandel that therapy for hepatitis C may 
have worsened the first patient’s clinical condi-
tion by inducing autoimmune hepatitis is entirely 
plausible, since interferon–ribavirin treatment is 
associated with autoimmune phenomena, such as 
autoimmune hemolytic anemia, in other body sys-
tems. Given that the precipitants of hemophago-
cytic lymphohistiocytosis in adults are for the 
most part not understood, however, and given the 
rarity of the condition, it is possible that what was 
observed simply represented the natural history of 
this serious disorder. Indeed, Tierney had cared 
for a patient with a clinical course nearly identi-
cal to that of this patient before these drugs were 
developed. Many factors may be responsible for 
initiating the hyperfunction of macrophages; this 
common end point makes it difficult to identify 
the precipitating cause.
Netea et al. propose an elegant therapeutic 
alternative in anakinra, which offers the advan-
tage of highly selective suppression of immune 
function and may minimize toxicity. The effects 
of treatment with anakinra are difficult to study 
since the number of adult patients with hemo-
phagocytic lymphohistiocytosis is so small. The 
greater incidence in children, especially in Asia, 
which is quite often associated with Epstein–Barr 
virus infection, might make this fertile ground for 
such investigation, but it cannot be assumed that 
the pathogenesis in the pediatric and adult popu-
lations is similar. It is not clear whether the use 
of anakinra is applicable to both children and 
adults, but surely the idea is sound.
Sandoval suggests that the second patient men-
tioned in the case should be tested for mutations 
in SH2DIA and BIRC4, which may be associated with 
fatal infection with Epstein–Barr virus in young 
men. Genetic testing was performed before this 
patient died, and no mutations were found.
Lawrence Tierney, M.D.
VA Medical Center 
San Francisco, CA
Amy C. Sievers, M.D.
Dana–Farber Cancer Institute 
Boston, MA
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
The New England Journal of Medicine 
Downloaded from nejm.org at RADBOUD UNIVERSITEIT NIJMEGEN on February 11, 2013. For personal use only. No other uses without permission. 
 Copyright © 2011 Massachusetts Medical Society. All rights reserved. 
